Variable | Training cohort (n = 217) | Validation cohort (n = 107) | |||||||
---|---|---|---|---|---|---|---|---|---|
csPCa (n = 68) | Non-CsPCa (n = 149) | P | CsPCa (n = 36) | Non-CsPCa (n = 71) | P | ||||
Age (Years, mean ± SD) | 71.92 ± 8.99 | 67.34 ± 8.65 | <0.01 | 69.80 ± 8.92 | 68.12 ± 7.56 | 0.15 | |||
tPSA (ng/mL, median [IQR]) | 19.50 (12.00-42.50) | 10.00 (6.61-16.00) | <0.01 | 14.57 (8.50–61.00) | 9.00 (6.00-15.75) | <0.01 | |||
fPSA (ng/mL, median [IQR]) | 2.29 (1.21–5.86) | 1.44 (0.98–2.05) | <0.01 | 1.60 (0.99–7.76) | 1.32 (0.77–2.49) | 0.04 | |||
PV (ml, median [IQR]) | 37.14 (29.59-62.00) | 55.00 (38.00-70.50) | <0.01 | 48.5 (35.40-56.55) | 49.00 (34.04–77.75) | 0.22 | |||
PSAD (ng/mL/mL, median [IQR]) | 0.49 (0.30–0.96) | 0.18 (0.12–0.31) | <0.01 | 0.32 (0.20–1.18) | 0.16 (0.12–0.26) | <0.01 | |||
Gleason score | |||||||||
≤ 3 + 3 | 149 | 71 | |||||||
3 + 4 | 37 | 12 | |||||||
4 + 3 | 18 | 4 | |||||||
4 + 4 | 2 | 4 | |||||||
> 4 + 4 | 11 | 16 |